Zimbabwe has declined a significant US healthcare agreement valued at 367 million US dollars (272 million pounds) over five years because of the United States' request for sensitive biological samples.
This rejection became public after a government memo from December was disclosed, which showed Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
A government representative later stated that the United States was demanding access to health data for scientific study and commercial gain while was not willing to share the benefits from future treatments.
"We will now turn to the difficult and regrettable process of winding down our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had donated more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged more negotiations to secure a agreement acceptable to both sides so the nation's vital HIV programme can continue.
Broader Context
Zimbabwe's decision comes after a similar case in Kenya, where a high court suspended a similar health funding agreement following concerns were filed about the security of Kenyans' medical information.
Since returning to office recently, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump argued its expenditure was "inefficient" and his government was pursuing direct bilateral agreements to enhance transparency and responsibility.
According to reports, 16 African countries have to date agreed to these new agreements, representing over $18.3bn in committed funds.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation would have delivered extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently receiving antiretroviral therapy via US-supported programmes," Tremont added.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, without any corresponding promise of access to any medical innovations – like new medicines or tests – that might result from that shared data," he stated.
"Put simply, our country would provide the basic resources for medical research with no assurance that the final treatments would be accessible to our people should a new pandemic emerge."
Sovereignty and Global Health
Mangwana further said that the American exit from the global health body and its push of one-on-one deals were disrupting structures already set up via the global health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme created to manage potential global health emergencies.
"This mechanism is designed to guarantee that when a nation contributes its data, the benefits – including medicines and cures – are shared equitably, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "are not meant as anti-American sentiment," he added.
"We welcome continued dialogue with our US partners on how future co-operation might be designed in a way that respects the independence and dignity of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but urged that talks need to persist given that a large portion of the nation's Aids initiatives relied on international support.
"In cases where technical issues arise, such as those involving data governance or agreement terms, these can frequently be resolved via technical clarification and negotiated safeguards," the group said.
The situation highlights the ongoing tensions between receiving crucial international aid and safeguarding local interests in an increasingly data-driven world.